XML 95 R46.htm IDEA: XBRL DOCUMENT v3.21.1

Share-Based Payments (Tables)

12 Months Ended

Dec. 31, 2020

Employee Equity Plan

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Schedule of Number and Share Price of Restricted Stock Units

Reconciliation of Outstanding Share-Options

		Restricted Stock Units (expected to be allocated)	Share price (in €)
As of January 1, 2020		-	-
Expected to be allocated under LTI Program		252,766	66.43
Expected to be allocated under LTI-plus Program		396,938	66.43
As of December 31, 2020		649,704	66.43

Schedule of Expense Recognized for Employee Services Received

Expense recognized in the Consolidated Statements of Operations

		Year ended December 31,
(in thousands)		2020
Cost of sales		€179
Research and development expenses		681
Sales and marketing expenses		8
General and administrative expenses		147
Total		€1,015

Management Board Grant

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Schedule of Expense Recognized for Employee Services Received

The expenses recognized for employee services received during the periods indicated are shown in the following table:

		Year ended December 31,
(in thousands)		2020
Research and development expenses		€1,514
General and administrative expenses		1,246
Total		€2,760

Schedule of Number and Weighted-Average Exercise Price of Share Options

The share options allocated and expected to be allocated to BioNTech’s Management Board as of the dates indicated are presented in the tables below.

		Share options (expected to be allocated)	Weighted-average exercise price (€)
As of January 1, 2020		-	-
Granted as of allocation date February 13, 2020		248,096	28.32
Expected to be allocated as of estimated allocation date 2021		101,422	67.26*
Expected to be allocated as of estimated allocation date 2022		102,463	67.27*
As of December 31, 2020		451,981	45.89

*Valuation parameter derived from the Monte-Carlo simulation model

The share options allocated and expected to be allocated under the Management Board Grant were as follows:

Allocation date February 13, 2020		Share options outstanding	Weighted-average exercise price (€)
Prof. Ugur Sahin, M.D.		97,420	28.32
Sean Marett		38,968	28.32
Dr. Sierk Poetting		38,968	28.32
Dr. Özlem Türeci, M.D.		38,968	28.32
Ryan Richardson		33,772	28.32

Estimated allocation date 2021		Share options outstanding (expected to be allocated)	Weighted-average exercise price (€)
Prof. Ugur Sahin, M.D.		39,826	67.26*
Sean Marett		15,930	67.26*
Dr. Sierk Poetting		15,930	67.26*
Dr. Özlem Türeci, M.D.		15,930	67.26*
Ryan Richardson		13,806	67.26*

*Valuation parameter derived from the Monte-Carlo simulation model

Estimated allocation date 2022		Share options outstanding (expected to be allocated)	Weighted-average exercise price (€)
Prof. Ugur Sahin, M.D.		39,817	67.27*
Sean Marett		15,927	67.27*
Dr. Sierk Poetting		15,927	67.27*
Dr. Özlem Türeci, M.D.		15,927	67.27*
Ryan Richardson		14,865	67.27*

*Valuation parameter derived from the Monte-Carlo simulation model

The share options outstanding as of December 31, 2020 issued to the Management Board Grant were as follows:

		Share options outstanding	Number of ordinary shares underlying options	Weighted-average exercise price (€)
Prof. Ugur Sahin, M.D.		101,686	1,830,348	10.14
Sean Marett		33,895	610,110	10.14
Dr. Sierk Poetting		33,895	610,110	10.14
Dr. Özlem Türeci, M.D.		108,463*	1,952,334	10.14
Ryan Richardson**		8,306***	149,508	10.14

*     Options fully vested on March 16, 2019, however these options will not become exercisable until September 16, 2022.

**   Ryan Richardson was appointed to the Management Board as Chief Strategy Officer (CSO) and Managing Director on January 12, 2020. The share options granted on November 15, 2018 under the Employee Stock Ownership Plan were granted before his appointment to the Management Board.

*** Options fully vested on October 10, 2019, however these options will not become exercisable until September 16, 2022.

Summary of Inputs Used in Measurement of Fair Value at Grant Date

The parameters used for measuring the fair values as of the respective (estimated) allocation dates were as follows:

		Allocation date February 13, 2020	Estimated allocation date  2021	Estimated allocation date 2022
Weighted average fair value*		€10.83	€26.85	€26.61
Weighted average share price		€28.20	€ 66.43*	€ 66.43*
Exercise price		€28.32	€ 67.26*	€ 67.27*
Expected volatility (%)		36.6%	41.0%	40.7%
Expected life (years)*		4.75	5.01	6.05
Risk-free interest rate (%)		1.61 %	0.88%	0.88%

*Valuation parameter derived from the Monte-Carlo simulation model

Chief Executive Officer Grant

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Summary of Inputs Used in Measurement of Fair Value at Grant Date

The inputs used in the measurement of the fair value at grant date of the Chief Executive Officer Grant were as follows:

		Grant date October 10, 2019
Weighted average fair value		€5.63
Weighted average share price		€13.60
Exercise price		€13.60
Expected volatility (%)		41.4%
Expected life (years)		5.37
Risk-free interest rate (%)		1.52 %

Employee Stock Ownership Plan

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Schedule of Expense Recognized for Employee Services Received

The expenses recognized for employee services received during the periods indicated are shown in the following table:

		Years ended December 31,
(in thousands)		2020	2019	2018
Cost of sales		€869	€896	€114
Research and development expenses		11,120	20,016	6,786
Sales and marketing expenses		111	108	13
General and administrative expenses		4,975	6,008	728
Total		€17,075	€27,028	€7,641

Schedule of Number and Weighted-Average Exercise Price of Share Options

Set out below is an overview of changes to share options outstanding and number of ordinary shares underlying these options that occurred during the periods indicated:

		Share options outstanding	Number of ordinary shares underlying options	Weighted-average exercise price (€)
As of January 1, 2019		658,109	11,845,962	10.14
Granted		14,511	261,198	15.17
Forfeited		(17,237)	(310,266)	10.85
As of December 31, 2019		655,383	11,796,894	10.23
As of January 1, 2020		655,383	11,796,894	10.23
Forfeited		(9,491)	(170,838)	10.81
As of December 31, 2020		645,892	11,626,056	10.23

Summary of Inputs Used in Measurement of Fair Value at Grant Date

The inputs used in the measurement of the fair values at grant date of the ESOP was as follows:

		Grant date 15 November 2018	Grant dates between February 21 - April 3, 2019	Grant dates between April 29 - May 31, 2019	Grant date December 1, 2019
Weighted average fair value		€7.41	€6.93	€7.04	€9.49
Weighted average share price		€14.40	€15.72	€16.03	€19.84
Exercise price		€10.14	€15.03	€15.39	€15.82
Expected volatility (%)		46.0%	46.0%	46.0%	46.0%
Expected life (years)		5.84	6.00	6.00	5.50
Risk-free interest rate (%)		0.05%	0.05%	0.05%	0.05%

X

- Definition

The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2020-01-01
-Paragraph 47
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_47_a&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IFRS
-Number 2
-IssueDate 2020-01-01
-Paragraph 45
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2020-01-01
-Paragraph 45
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The explanation that enables users of financial statements to understand the effect of share-based payment transactions on the entity's profit (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2020-01-01
-Paragraph 50
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_50&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss
Namespace Prefix:	ifrs-full_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: